Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness... see more

NDAQ:INM - Post Discussion

InMed Pharmaceuticals Inc > NASDAQ requirements
View:
Post by Linc1581 on Jul 27, 2020 1:53pm

NASDAQ requirements

well inmed is under the requirements now for listing. Will continue to bleed...they will also dilute still to keep money in the bank for operations which will be 65-70% dilution.
Comment by MeanGreen on Jul 27, 2020 2:44pm
I believe it's the closing price that matters. As long as they're above $4 USD at close it should be fine 
Comment by Linc1581 on Jul 27, 2020 2:55pm
even if they get uplisted are they going to offer the 12 million USD at 3.50 USD? There needs to be some incentive for new investors to buy into it below market price. This will be 70-85% dilution of existing shareholders...not looking good at all.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities